Search results for "Urea"

showing 10 items of 888 documents

Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outs…

2021

Background ADVanced Organ Support (ADVOS) is a novel type of extracorporeal albumin dialysis and holds promise to sustain liver function and recovery of patients with acute-on-chronic liver failure (ACLF). Previously, ADVOS was tested as continuous treatment for intensive care patients with liver failure. Data related to the applicability and safety as discontinuous treatment outside of ICU is not available. Aim Evaluation of ADVOS as discontinuous treatment for patients with ACLF outside intensive care unit and comparison with a matched historic cohort. Methods and results In this retrospective study, 26 patients with ACLF and the indication for renal replacement therapy related to HRS-AK…

MalePhysiologymedicine.medical_treatmentLiver transplantationToxicologyPathology and Laboratory MedicineSeverity of Illness IndexBiochemistrylaw.inventionBlood Urea Nitrogen0302 clinical medicinelawLiver Cirrhosis AlcoholicMedicine and Health SciencesMedicineBileMultidisciplinaryLiver DiseasesQRMiddle AgedIntensive care unitBody FluidsRenal Replacement TherapyLiverCirrhosisNephrologyCreatinineMedicine030211 gastroenterology & hepatologyFemaleHemodialysisAnatomyDetoxificationResearch Articlemedicine.medical_specialtyCritical CareScienceSurgical and Invasive Medical ProceduresGastroenterology and Hepatology03 medical and health sciencesDigestive System ProceduresRenal DialysisIntensive careInternal medicineAlbuminsMedical DialysisHumansRenal replacement therapyDialysisRetrospective StudiesTransplantationbusiness.industryAcute-On-Chronic Liver FailureBiology and Life SciencesProteins030208 emergency & critical care medicineRetrospective cohort studyBilirubinOrgan TransplantationSurvival AnalysisLiver TransplantationPatient ComplianceLiver functionbusinessBiomarkersPLoS ONE
researchProduct

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct

Hypoxemia Adds to the CURB-65 Pneumonia Severity Score in Hospitalized Patients With Mild Pneumonia

2011

BACKGROUND: Hypoxemia may influence the prognosis of patients with mild pneumonia, regardless of the initial CURB-65 score (confusion, blood urea nitrogen > 20 mg/dL, respiratory rate > 30 breaths/min, blood pressure < 90/60 mm Hg, and age ≥ 65 y). OBJECTIVE: To determine the risk factors associated with hypoxemia and the influence of hypoxemia on clinical outcomes in hospitalized patients with mild pneumonia. METHODS: We performed a multicenter prospective cohort study of 585 consecutive hospitalized patients with mild pneumonia (CURB-65 groups 0 and 1). We stratified the patients according to the presence of hypoxemia, defined as a PaO2/FIO2 < 300 mm Hg on admission. We assessed the risk …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyBlood PressureCritical Care and Intensive Care MedicineSeverity of Illness IndexBlood Urea Nitrogenlaw.inventionHypoxemiaRisk FactorslawInternal medicineIntensive caremedicineHumansHospital MortalityProspective StudiesHypoalbuminemiaConfusionHypoxiaAgedInpatientsCOPDbusiness.industryPneumoniaGeneral MedicineOdds ratioPrognosismedicine.diseaseCURB-65Intensive care unitrespiratory tract diseasesSurgeryIntensive Care UnitsPneumoniaRespiratory MechanicsFemalemedicine.symptombusinessFollow-Up StudiesRespiratory Care
researchProduct

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

2019

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; media…

MalePyridinesmedicine.medical_treatment030230 surgeryLiver transplantationchemotherapyGastroenterologychemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyPharmacology (medical)Liver NeoplasmsMiddle AgedSorafenibPrognosisRecurrent Hepatocellular Carcinomaside effectsHepatocellular carcinomaFemalemedicine.drugSorafenibAdultmedicine.medical_specialtyCarcinoma Hepatocellularcancer/malignancy/neoplasiaclinical research/practice03 medical and health sciencesYoung AdultInternal medicineRegorafenibmedicineHumansAdverse effectAgedRetrospective StudiesTransplantationdrug interactionPerformance statusbusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationLiver TransplantationchemistryDrug Resistance NeoplasmNeoplasm Recurrence Localpharmacologybusinessliver transplantation/hepatologyFollow-Up Studies
researchProduct

Retinas of the Diurnal RodentArvicanthis ansorgeiAre Highly Resistant to Experimentally Induced Stress and Degeneration

2011

International audience; PURPOSE. Environmentally induced stress plays a significant role in retinal degeneration and blindness both in animals and in humans. Among such sources of stress, phototoxicity is well studied and has been shown to lead to photoreceptor-specific loss in a number of species. However, the vast majority of studies have been conducted in nocturnal, albino rod-dominant rat and mouse strains, and the pertinence of such findings to human pathology and cone loss is debatable. The authors examined retinal vulnerability to damage in the diurnal murid rodent Arvicanthis ansorgei, a pigmented species with a large number of cones. METHODS. The authors used established protocols …

MaleRetinal degenerationLightRodentsprague dawlayFatty Acids Nonesterifiedbright cyclic lightMicechemistry.chemical_compound0302 clinical medicine[SDV.IDA]Life Sciences [q-bio]/Food engineeringoxidative stressmethyl-N-nitrosoufrea0303 health sciencesbiologymedicine.diagnostic_testmouse retinaRetinal DegenerationMethylnitrosoureaAnatomydocosahexaenoic acidCircadian Rhythmmedicine.anatomical_structureDocosahexaenoic acidRetinal Cone Photoreceptor CellsN-3 fatty acidsPhototoxicityAlkylating Agentsmedicine.medical_specialtylight-induced degeneration03 medical and health sciencesSpecies SpecificityStress Physiologicalbiology.animalInternal medicineElectroretinographymedicineAnimals[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering030304 developmental biologyRetinaRetinalmedicine.diseaseMice Inbred C57BLMuridaeratsTissue DegenerationDisease Models AnimalEndocrinologyrhodopsinchemistryregenerationinduced photoreceptor apoptosis030221 ophthalmology & optometrysense organsElectroretinographyInvestigative Opthalmology &amp; Visual Science
researchProduct

In vivo antigenotoxic effects of dietary allyl sulfides in the rat

1997

The effects of dietary administration of diallyl sulfide (DAS), diallyl disulfide (DADS) and allyl mercaptan (AM) on the genotoxicity of different chemicals were studied in two experimental systems: (i) measurement of hepatic DNA single-strand breaks induced in rats by aflatoxin B1 (AFB1), N-nitrosodimethylamine (NDMA) or methylnitrosourea (MNU); (ii) mutagenicity of AFB1 or NDMA on Salmonella typhimurium TA100 using hepatic S9 from rats fed allyl sulfides as the activation system. All compounds strongly reduced hepatic DNA breaks induced by AFB1 and NDMA but did not modify the genotoxicity of MNU. In the Ames test, the mutagenicity of NDMA was strongly inhibited by hepatic S9 from rats fed…

MaleSalmonella typhimuriumCancer ResearchAflatoxin B1[SDV]Life Sciences [q-bio]Allyl compoundMutagenSulfidesmedicine.disease_cause030226 pharmacology & pharmacyDimethylnitrosamineAmes test03 medical and health scienceschemistry.chemical_compound0302 clinical medicineN-NitrosodimethylaminemedicineAnimalsAnticarcinogenic AgentsDisulfidesComputingMilieux_MISCELLANEOUSMutagenicity TestsDiallyl disulfidefood and beveragesAntimutagenic AgentsMethylnitrosoureaRats3. Good healthAllyl Compounds[SDV] Life Sciences [q-bio]LiverOncologychemistryBiochemistry030220 oncology & carcinogenesisRATAllyl MercaptanCARCINOGENESEAllyl SulfideGenotoxicityDNA DamageMutagensCancer Letters
researchProduct

Colorectal cancer in patients with type 2 diabetes mellitus: a single-center experience

2017

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of colorectal cancer (CRC). The aim of the study is to evaluate the prevalence of CRC in a cohort of Caucasian patients with T2DM and the association with other variables previously known to be related with increased risk of CRC. We retrospectively evaluated the data of 741 consecutive Caucasian patients with T2DM who underwent colonoscopic screening in our tertiary referral center. A control cohort of 333 patients with thyroid disease was selected to evaluate the difference in the incidence of CRC. At a median follow-up of 132.5 months (range 33.3-175.7), 67 cases of cancer (prevalence 9%) occurred; among these, 14 cases …

MaleSettore MED/12 - GastroenterologiaMiddle AgedRisk Assessmentcolorectal cancer diabetes mellitu 2 typeMetforminWhite PeopleSettore MED/18 - Chirurgia GeneraleSulfonylurea CompoundsDiabetes Mellitus Type 2Risk FactorsCase-Control StudiesInsulin SecretionHumansHypoglycemic AgentsInsulinFemaleColorectal NeoplasmsAgedRetrospective Studies
researchProduct

Blood-Borne Markers of Fatigue in Competitive Athletes – Results from Simulated Training Camps

2016

Assessing current fatigue of athletes to fine-tune training prescriptions is a critical task in competitive sports. Blood-borne surrogate markers are widely used despite the scarcity of validation trials with representative subjects and interventions. Moreover, differences between training modes and disciplines (e.g. due to differences in eccentric force production or calorie turnover) have rarely been studied within a consistent design. Therefore, we investigated blood-borne fatigue markers during and after discipline-specific simulated training camps. A comprehensive panel of blood-born indicators was measured in 73 competitive athletes (28 cyclists, 22 team sports, 23 strength) at 3 time…

MaleTeam sportPhysiologylcsh:MedicinePathology and Laboratory MedicineMaterial FatigueInterval training0302 clinical medicineMaterials PhysicsMedicine and Health SciencesHuman PerformanceUreaMedicineEccentricPublic and Occupational Healthlcsh:ScienceFatigueMultidisciplinarybiologyOrganic CompoundsPhysicsClassical MechanicsHematologyVenous bloodSports ScienceBody FluidsChemistryBloodPhysical SciencesStrength TrainingFemaleAnatomyStatistics (Mathematics)Research ArticleSportsmedicine.medical_specialtyStrength trainingMaterials Science03 medical and health sciencesSigns and SymptomsAnimal scienceConfidence IntervalsHumansSports and Exercise MedicineExerciseDamage MechanicsBehaviorbusiness.industryAthletesOrganic Chemistrylcsh:RChemical CompoundsBiology and Life Sciences030229 sport sciencesbiology.organism_classificationConfidence intervalPhysical FitnessAthletesbiology.proteinPhysical therapyRecreationlcsh:QCreatine kinasebusinessMathematicsBiomarkers030217 neurology & neurosurgeryPLOS ONE
researchProduct

Effect of Thyroid Hormones on Urea Biosynthesis and Related Processes in Rat Liver*

1988

The results of the few studies on the effect of the thyroid status on nitrogen metabolism have been inconclusive and/or contradictory. In an attempt to elucidate this important relationship, we have studied the effect of experimental hypo- and hyperthyroidism on urea biosynthesis and related processes. We have found that the capacity of the liver to synthesize urea was increased in hypothyroid rats, as were the activities of the urea cycle enzymes; there were also changes in the activities of some related enzymes and in the levels of intermediates and amino acids. Isolated hepatocytes from these rats showed an increased capacity for urea synthesis. In hyperthyroid rats the picture was more …

MaleThyroid Hormonesendocrine systemmedicine.medical_specialtyendocrine system diseasesCarbamoyl-Phosphate Synthase (Ammonia)HyperthyroidismIodide PeroxidaseGlucagonchemistry.chemical_compoundEndocrinologyGlutamatesHypothyroidismBiosynthesisAmmoniaInternal medicineCyclic AMPmedicineAnimalsUreaAmino AcidsOrnithine Carbamoyltransferasechemistry.chemical_classificationCatabolismRats Inbred StrainsMetabolismGlucagonRatsAmino acidThyroxineEndocrinologymedicine.anatomical_structureLiverchemistryBiochemistryUrea cycleHepatocyteUreaTriiodothyroninehormones hormone substitutes and hormone antagonistsEndocrinology
researchProduct

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (R…

2015

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy…

MaleTime FactorsKaplan-Meier EstimateGastroenterologyLiver diseaseClinical endpoint610 Medicine &amp; healthramucirumab sorafenib HCCAged 80 and overeducation.field_of_studyLiver NeoplasmsRemission InductionAntibodies MonoclonalMiddle AgedSorafenibTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaFemaleSurvival AnalysiHumanmedicine.drugAdultNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorPopulationAntibodies Monoclonal HumanizedPlaceboDisease-Free SurvivalDrug Administration ScheduleFollow-Up StudieRamucirumabDouble-Blind MethodInternal medicineConfidence IntervalsmedicineCarcinomaHumanseducationProportional Hazards ModelsAgedDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsPatient Selectionmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryProportional Hazards ModelbusinessConfidence IntervalFollow-Up StudiesThe Lancet Oncology
researchProduct